EYEPOINT PHARMACEUTICALS INC (EYPT)

Company Profile

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 144 full-time employees. The company went IPO on 2005-01-27. The firm is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The firm's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, an investigational sustained delivery intravitreal treatment in Phase II clinical trials. The Company’s commercial product, YUTIQ, is a once-every-three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye that utilizes a non-erodible formulation of Durasert. Its commercial product also includes DEXYCU, which is administered as a single dose directly into the surgical site at the end of ocular surgery and is a long-acting intraocular product for the treatment of post-operative inflammation. Its other products include ILUVIEN, Retisert, and Vitrasert.

Company Info

EYEPOINT PHARMACEUTICALS INC

480 Pleasant St Ste B300

Watertown MASSACHUSETTS 02472

P: 16179265000

CEO: Nancy Lurker

Employees: 144

Website: https://eyepointpharma.com/